Compare
QHSLab, Inc. vs Femasys Inc vs Vycor Medical Inc vs Tenon Medical, Inc.
| Latest fiscal year | QHSLab, Inc. USAQ | Femasys Inc FEMY | Vycor Medical Inc VYCO | Tenon Medical, Inc. TNON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.69M | $2.29M | $1.86M | $3.94M |
| Revenue growth (YoY) | +26.3% | +40.8% | +17.2% | +20.4% |
| Gross margin | 67.3% | 62.0% (computed) | 83.8% | 59.8% |
| Operating margin | 4.9% | -767.0% | 1.8% | -324.3% |
| Net margin | 17.0% | -812.3% | -3.9% | -318.4% |
| Net income | $457.4K | -$18.63M | -$72.4K | -$12.56M |
| EPS (Diluted) | $0.02 | -$0.47 | -$0.01 | -$1.70 |
| Operating cash flow | $178.1K | -$18.69M | -$13.5K | -$10.74M |
| Free cash flow | n/a | -$19.22M | -$18.7K | -$11.02M |
| Cash & equivalents | $636.2K | $9.27M | $87.0K | $3.76M |
| Total assets | $2.17M | $20.72M | $830.4K | $10.76M |
| Total liabilities | $546.1K | $14.85M | $4.92M | $5.72M |
| Shareholders' equity | $1.62M | $5.87M | -$4.09M | $5.04M |
| Return on year-end equity | 28.1% | -317.4% | n/a | -249.1% |
| Shares outstanding | 15.03M | 59.60M | 33.37M | 10.85M |
Revenue, most recent five fiscal years
| Fiscal year | QHSLab, Inc. | Femasys Inc | Vycor Medical Inc | Tenon Medical, Inc. |
|---|---|---|---|---|
| Latest | $2.69M Ended 2025-12-31 | $2.29M Ended 2025-12-31 | $1.86M Ended 2025-12-31 | $3.94M Ended 2025-12-31 |
| 1 year earlier | $2.13M Ended 2024-12-31 | $1.63M Ended 2024-12-31 | $1.59M Ended 2024-12-31 | $3.28M Ended 2024-12-31 |
| 2 years earlier | $1.41M Ended 2023-12-31 | $1.07M Ended 2023-12-31 | $1.46M Ended 2023-12-31 | $2.93M Ended 2023-12-31 |
| 3 years earlier | $1.24M Ended 2022-12-31 | $1.21M Ended 2022-12-31 | $1.22M Ended 2022-12-31 | $691.0K Ended 2022-12-31 |
| 4 years earlier | $1.41M Ended 2021-12-31 | $1.18M Ended 2021-12-31 | $1.39M Ended 2021-12-31 | $160.0K Ended 2021-12-31 |